Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04459715

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Squamous Cell Carcinoma of the Head and Neck Clinical Trial

Official title:
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Clinical Trial Summary

The primary objective of the study is to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04459715
Study type Interventional
Source EMD Serono
Contact
Status Active, not recruiting
Phase Phase 3
Start date August 7, 2020
Completion date April 30, 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT06236464 - Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas
Terminated NCT04659369 - Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT02572778 - Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Terminated NCT01488318 - Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT00999700 - Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin Phase 3
Completed NCT02565758 - ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02543476 - SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) N/A
Recruiting NCT03938012 - Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma
Terminated NCT02124850 - A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab Phase 1
Active, not recruiting NCT03313804 - Priming Immunotherapy in Advanced Disease With Radiation Phase 2
Recruiting NCT05208762 - A Study of SGN-PDL1V in Advanced Solid Tumors Phase 1
Terminated NCT04453046 - Hemopurifier Plus Pembrolizumab in Head and Neck Cancer N/A
Completed NCT01758731 - Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History Phase 1
Completed NCT02473731 - A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients Phase 1
Completed NCT02022098 - Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial N/A
Completed NCT01458392 - Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck Phase 2
Completed NCT02882308 - Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. Phase 2